|
| Search for Cases |
|
Case Details |
|
Case Code: LAW007
|
| Case Length: 5 Pages |
| Period: 2016-2017 |
| Pub Date: 2016 |
| Teaching Note: Not Available |
| Price: Rs.200 |
| Organization :- |
Industry : Pharmaceutical
|
| Countries : India |
| Themes: -
|
|
|
|
|
Ban on Fixed Dose Combination Drugs in India Stokes Controversy |
|
|
|
|
| <<Previous Page |
INTRODUCTION |
| |
| The Indian pharmaceutical industry suffered a big blow on March 10, 2016, when the Indian Ministry of Health and Family Welfare prohibited the manufacture, sale, and distribution of 344 drugs, extending to about 6,000 brands, having fixed dose combinations (FDCs) relating them to health risks. Use of FDCs was widespread in the Indian market and many of them could be obtained over the counter. The drug companies combined different drugs into a single unit and marketed them as new products for common ailments. The use of FDCs was quite common among patients and doctors in India and the drugs were used in every therapeutic area. They were popular in India because of their convenience and low cost and because they were useful in the treatment of contagious diseases like malaria and tuberculosis. They were also useful for chronic conditions where multiple disorders existed in a patient. FDCs were more useful if two or more drugs were prescribed for different schedules like once or twice a day. Patients also felt that it was easier to remember to take one medication in the form of FDCs rather than two or more separate drugs. FDCs were also said to improve patient adherence to the medication schedule as they reduced the pill burden... .
|
| |
 |
| or |
 |
| or |
PayPal (4 USD)
|
|
|
| |
|
Exhibit I: Drug Categories Affected by Ban on FDCs
Exhibit II: The Estimated Amount of Loss per Year for Drug Companies Due to Ban on FDCs
|
| |
| |
|
| |
|
|
|
